Dual-receptor targeting of type I dendritic cells with DNA-scaffolded nanoparticles enhances STING-licensed antitumor immunity
Open Access
- 2 January 2026
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (1) , eaeb0452
Abstract
Activating the stimulator of interferon genes (STING) pathway in conventional type I dendritic cells (cDC1s) is crucial for inhibiting solid tumor metastasis. A major hurdle is the cell type–specific delivery of immune agonists. To overcome this, we created a DNA-scaffolded poly(lactic- co -glycolic acid) nanoparticle platform for precisely loading antibodies targeting cDC1 receptors, specifically DEC205 and Clec9A. Optimizing these targeting ligands revealed a 1:1 ratio as ideal for preferentially targeting splenic cDC1s in vivo. When the STING agonist MSA-2 was delivered via this platform, termed programmable and ratiometrically-engineered immunomodulatory nanoparticle (PRIME NP), its immunostimulatory activity significantly increased. In CT26 tumor–bearing mice, PRIME NP treatment triggered robust proinflammatory signaling and activated both innate and adaptive immune responses, leading to potent CD8 + T cell–driven tumor regression and long-term survival in preclinical models. This work provides a framework for designing actively targeted particles and emphasizes DNA-scaffolded nanoparticles as an effective strategy to enhance the STING-cDC1 pathway for solid tumor treatment.Keywords
Funding Information
- National Institutes of Health (R25 HL088992)
- National Institutes of Health (R25 HL088992)
- National Center for Research Resources (1S10RR021051)
- Roche France (MBTDSIO44)
This publication has 39 references indexed in Scilit:
- Cytotoxic CD8+ T cells in cancer and cancer immunotherapyBritish Journal of Cancer, 2020
- An orally available non-nucleotide STING agonist with antitumor activityScience, 2020
- Targeting Antigens to Different Receptors on Conventional Type 1 Dendritic Cells Impacts the Immune ResponseThe Journal of Immunology, 2020
- A guide to cancer immunotherapy: from T cell basic science to clinical practiceNature Reviews Immunology, 2020
- Quantitative Study of the Interaction of Multivalent Ligand-Modified Nanoparticles with Breast Cancer Cells with Tunable Receptor DensityACS Nano, 2020
- STING pathway agonism as a cancer therapeuticImmunological Reviews, 2019
- Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?Frontiers in Immunology, 2019
- CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A reviewJournal of Cellular Physiology, 2018
- How Do Cytotoxic Lymphocytes Kill Cancer Cells?Clinical Cancer Research, 2015
- Differential Antigen Processing by Dendritic Cell Subsets in VivoScience, 2007